Yong Yu - 15 Dec 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
15 Dec 2023
Net transactions value
-$428,180
Form type
4
Filing time
18 Dec 2023, 16:15:20 UTC
Previous filing
08 Dec 2023
Next filing
08 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale $345,915 -26,732 -82% $12.94 5,803 15 Dec 2023 Direct F1
transaction GNLX Common Stock Sale $82,265 -5,803 -100% $14.18 0 15 Dec 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $12.9401, and the range of prices were between $12.69 and $13.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The weighted average sale price for the transaction reported was $14.1763, and the range of prices were between $13.80 and $14.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.